SEC Form 10-Q filed by Aligos Therapeutics Inc.
$ALGS
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/19/2024 | $75.00 | Buy | H.C. Wainwright |
| 1/6/2023 | $2.00 → $3.00 | Neutral → Overweight | Piper Sandler |
| 1/6/2023 | $2.50 → $3.00 | Hold → Buy | Jefferies |
| 3/23/2022 | $15.00 → $4.00 | Overweight → Neutral | Piper Sandler |
| 3/11/2022 | $47.00 → $15.00 | Overweight | Piper Sandler |
| 3/11/2022 | $10.00 → $11.00 | Outperform | SVB Leerink |
| 2/16/2022 | $15.00 → $10.00 | Outperform | SVB Leerink |
| 1/7/2022 | $30.00 → $12.00 | Overweight → Neutral | JP Morgan |
Key Opinion Leader (KOL) event with Dr. Mark Sulkowski to discuss his perspectives on the chronic suppression regulatory pathway and future development plans following positive feedback from the FDA to move forward with chronic HBV DNA suppression as the primary efficacy endpoint Scheduled for Thursday, July 18, 2024 at 3:00pm ET/12:00pm PTSOUTH SAN FRANCISCO, Calif., July 10, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos"))))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that it will host a virtual KOL event featuring Mark Sulkowski, MD, Johns Hopkin
Data from ≤72 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (90%) HBeAg-positive CHB subjects with no viral breakthrough. New data also showed that as HBeAg declined to near negativity in this patient population, anti-HBe antibody (HBeAb) levels exhibited a positive trend.
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced positive data from one late-breaker oral and three poster presentations at the American Association for the Study of Liver Disease's (AASLD) The Liver Meeting (TLM) 2024, being held November 15 – 19, 2024 in San Diego, CA. The clinical poster presentation highlighted the continued potent antiviral activity of ALG-000184 for chronic hepatitis B (CHB) virus infection in both HBeAg-positive and HBeAg-negative subjects, de
SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the third quarter 2024. "This quarter we reached a key milestone when we announced the positive topline HERALD data in MASH subjects," stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "With placebo-adjusted median relative reductions in liver fat of up to 46.2%, we continue to believe ALG-055009 has best-in-c
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), Aligos a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company's third quarter 2024 financial results on Wednesday, November 6, 2024, after the close of the U.S. financial markets. About Aligos Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven appro
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured by MRI-PDFFPlacebo-adjusted median relative reductions in liver fat were up to 46.2% with a clear dose responseALG-055009 was well-tolerated with no serious adverse events or dose reductions. Importantly, ALG-055009 dose groups had a similar incidence of gastrointestinal-related adverse events with less diarrhea compared to placeboSignificant reductions in atherogenic lipids, including LDL-C, lipoprotein (a), and apolipoprotein B were observedConference call scheduled for 8:30am ET/5:30am PT today SOUTH SAN FRANCISCO, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Alig
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", "Company"))), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Company will share the topline results from the Phase 2a HERALD study of ALG-055009, a thyroid hormone receptor beta (THR-β) agonist, in metabolic-dysfunction associated steatohepatitis (MASH) subjects on Thursday, September 19, 2024 prior to the market open. Following the announcement, the Company will host a conference call and webcast at 8:30am ET/5:30am PT. Conference Call & Webcast Details Th
CAM (ALG-000184) continues to demonstrate best in class potential in Phase 1bASO (ALG-020572) completed dosing in Phase 1a (HVs); Phase 1b study (CHB) initiated – 1st cohort fully enrolledsiRNA (ALG-125755) progressing on track through Phase 1 enabling nonclinical studiesTHR-β (ALG-055009) currently dosing in healthy volunteers and subjects with hyperlipidemiaMultiple COVID-19 3CL protease inhibitor drug candidates without need for ritonavir boosting identified – all more potent than nirmatrelvirMerck expanded the NASH research collaboration utilizing Aligos' proprietary oligonucleotide technology Cash, cash equivalents and investments of $205.8 million as of December 31, 2021 A sufficient
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
3 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
4 - Aligos Therapeutics, Inc. (0001799448) (Issuer)
EFFECT - Aligos Therapeutics, Inc. (0001799448) (Filer)
S-8 - Aligos Therapeutics, Inc. (0001799448) (Filer)
S-3 - Aligos Therapeutics, Inc. (0001799448) (Filer)
H.C. Wainwright initiated coverage of Aligos Therapeutics with a rating of Buy and set a new price target of $75.00
Piper Sandler upgraded Aligos Therapeutics from Neutral to Overweight and set a new price target of $3.00 from $2.00 previously
Jefferies upgraded Aligos Therapeutics from Hold to Buy and set a new price target of $3.00 from $2.50 previously
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of David Perry as Vice President of Business Development, effective immediately. "We are pleased to welcome David to the Aligos team during this exciting time for the company," said Lesley Ann Calhoun, Executive Vice President and Chief Financial Officer at Aligos. "David's expertise in leading valuable partnerships will be instrumental as we strategically look to maximize the potential of our best-in-class pipeline
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos", the "Company"))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced the appointment of Heather Preston, M.D. and Margarita Chavez, J.D. as Class II Independent Directors to the Board of Directors, effective August 7, 2024. Dr. Preston will join the Nominating and Corporate Governance Committee as Chair and Ms. Chavez will join the Audit Committee. "We are pleased to announce the appointment of Dr. Heather Preston and Margarita Chavez to our Board of Directors," stated
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)
SC 13G/A - Aligos Therapeutics, Inc. (0001799448) (Subject)